Journal Information
Original article
Safety and effectiveness of oral blonanserin for schizophrenia in adolescents in China: Data from a 12-week post-marketing surveillance
Yun Yua, Xijin Wangb, Ruiling Zhangc, Keqing Lid, Gang Wange,f, Jindong Cheng, Meijuan Sunh, Zhiyuan Xuni, Xiaodong Yangj, Guijun Zhaok, Haiyun Lil, Xuejun Liua,
Corresponding author
707151907@qq.com
Corresponding author at: Department of Psychiatry, Brain Hospital of Hunan Province, Changsha 410007, Hunan, China.
Corresponding author at: Department of Psychiatry, Brain Hospital of Hunan Province, Changsha 410007, Hunan, China.
a Department of Psychiatry, Brain Hospital of Hunan Province, Changsha 410007, Hunan, China
b Department of Psychiatry, the First Psychiatric Hospital of Harbin, Harbin 150010, Heilongjiang, China
c Department of Psychiatry, Henan Mental Hospital, Xinxiang 453002, Henan, China
d Department of Psychiatry, Hebei Provincial Mental Health Center, Baoding 071000, Hebei, China
e The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China
f Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100088, China
g Department of Psychiatry, and National Clinical Research Center for Mental Disorders, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China
h Department of Pharmacy, Daqing Third Hospital, Daqing 163712, Heilongjiang, China
i Department of Psychiatry, Tianjin Anding Hospital, Tianjin 300222, Tianjin, China
j Department of Psychiatry, Shandong Mental Health center, Jinan 250014, Shandong, China
k Department of Psychiatry, Guangyuan Mental Health Center, Guangyuan 628001, Sichuan, China
l Medical Affairs, Sumitomo Pharma (Suzhou) Co. Ltd. Shanghai 200025, Shanghai, China
Ver más